Nomura Asset Management CO LTD Intellia Therapeutics, Inc. Transaction History

Nomura Asset Management CO LTD

  • $31.8 Billion
  • Q3 2024
Number of Shares
0
Previous 0 NaN%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024
BUY
$19.72 - $27.36 $0 - $0
0 New
0 $0
Q2 2024

Aug 14, 2024
BUY
$20.02 - $27.22 $0 - $0
0 New
0 $0
Q1 2024

May 13, 2024
BUY
$23.82 - $32.8 $0 - $0
0 New
0 $0
Q4 2023

Feb 09, 2024
BUY
$23.16 - $32.34 $0 - $0
0 New
0 $0
Q3 2023

Nov 03, 2023
BUY
$31.62 - $45.78 $0 - $0
0 New
0 $0
Q2 2023

Aug 14, 2023
BUY
$34.58 - $46.03 $0 - $0
0 New
0 $0
Q1 2023

May 11, 2023
BUY
$33.3 - $44.82 $0 - $0
0 New
0 $0
Q4 2022

Feb 14, 2023
BUY
$33.21 - $62.69 $0 - $0
0 New
0 $0
Q3 2022

Nov 14, 2022
BUY
$53.92 - $71.7 $0 - $0
0 New
0 $0
Q3 2022

Nov 10, 2022
BUY
$53.92 - $71.7 $0 - $0
0 New
0 $0
Q3 2022

Nov 10, 2022
BUY
$53.92 - $71.7 $0 - $0
0 New
0 $0
Q2 2022

Aug 12, 2022
SELL
$38.49 - $76.21 $140,873 - $278,928
-3,660 Closed
0 $0
Q4 2021

Feb 01, 2022
BUY
$100.76 - $138.36 $368,781 - $506,397
3,660 New
3,660 $433,000
Q3 2021

Nov 12, 2021
BUY
$132.37 - $176.78 $0 - $0
0 New
0 $0
Q2 2021

Aug 06, 2021
BUY
$60.88 - $161.91 $0 - $0
0 New
0 $0
Q1 2021

May 14, 2021
BUY
$46.59 - $83.68 $0 - $0
0 New
0 $0
Q4 2018

Feb 12, 2019
SELL
$11.39 - $27.13 $0 - $0
0 Closed
0 $0
Q3 2018

Nov 07, 2018
BUY
$25.78 - $32.6 $0 - $0
0 New
0 $0
Q2 2018

Aug 03, 2018
BUY
$20.02 - $30.79 $0 - $0
0 New
0 $0

Others Institutions Holding NTLA

# of Institutions
313
Shares Held
91.5M
Call Options Held
442K
Put Options Held
880K
View Full List

About Intellia Therapeutics, Inc.

NTLA Quotes by TradingView
  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.09B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Nomura Asset Management CO LTD Portfolio

Follow Nomura Asset Management CO LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nomura Asset Management CO LTD, based on Form 13F filings with the SEC.

News

Stay updated on Nomura Asset Management CO LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email